Trinity Biotech

Trinity Biotech Short-term Debt

The Short-Term Debt of Trinity Biotech (TRIB) as of Oct 15, 2026 is 110.81 M USD. In the previous year, Short-Term Debt was 2.50 M USD — a change of 4,341.40% (higher).

Short-term Debt

110.81 MUSD

YoY

4,341.40%

Last updated:

Short-Term Debt of Trinity Biotech is 2025 110.81 M USD. Short-Term Debt of Trinity Biotech was 2024 2.50 M USD. It decreases by 4,341.40% higher compared to the previous year.

The Trinity Biotech Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2018
436,000.00 USD
Jan 1, 2019
2.40 M USD
Jan 1, 2020
5.06 M USD
Jan 1, 2021
85.29 M USD
Jan 1, 2022
1.89 M USD
Jan 1, 2023
1.90 M USD
Jan 1, 2024
2.50 M USD
Jan 1, 2025
110.81 M USD
The Trinity Biotech Short-term Debt history
YEARShort-term DebtYoY
110.81 MUSD+4,341.40%
2.50 MUSD+31.04%
1.90 MUSD+0.95%
1.89 MUSD-97.79%
85.29 MUSD+1,586.28%
5.06 MUSD+110.40%
2.40 MUSD+451.38%
436,000.00USD+23.16%
354,000.00USD+29.67%
273,000.00USD+0.74%
271,000.00USD-97.69%
11.73 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech PLC is a healthcare company based in Bray, Ireland, with a focus on developing, manufacturing, and marketing medical diagnostic products. The company serves the clinical laboratory and point-of-care segments of the diagnostic market. Trinity Biotech employs 579 full-time staff and has been publicly traded since its IPO on October 21, 1992. Its products are designed to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company operates through two geographic segments: the Americas and Rest of World. Product categories include point-of-care diagnostics, emergency medicine diagnostics, clinical laboratory reagents, and blood bank screening. The company's point-of-care brands are Uni-Gold and Recombigen, while its emergency medicine diagnostics cover acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. Trinity Biotech supplies the clinical laboratory market with reagent products and other solutions through its clinical chemistry business. The blood bank screening division manufactures products to screen donated blood for transfusion-transmissible infections. The company's website is www.trinitybiotech.com. Trinity Biotech PLC is listed on the stock market under the ticker TRIB and ISIN US8964385046. The company's headquarters are located in Bray, Wicklow, Ireland. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Short-Term Debt of Trinity Biotech is 110.81 M USD in 2025.

Short-Term Debt of Trinity Biotech changed from 2.50 M USD to 110.81 M USD, representing a 4,341.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Trinity Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Trinity Biotech

All Key Metrics — Trinity Biotech